DESIGN FOR FDA: A PREDICTIVE MODEL FOR THE FDA'S DECISION TIME FOR MEDICAL DEVICES

被引:0
|
作者
Medina, Lourdes A. [1 ]
Davila, Saylisse [1 ]
Kremer, Guel E. Okudan [2 ,3 ]
Wysk, Richard A. [4 ]
机构
[1] Univ Puerto Rico, Dept Ind Engn, Mayaguez, PR 00681 USA
[2] Penn State Univ, Sch Engn Design, University Pk, PA 16802 USA
[3] Penn State Univ, Dept Ind & Mfg Engn, University Pk, PA 16802 USA
[4] N Carolina State Univ, Dept Ind & Syst Engn, Raleigh, NC 27695 USA
来源
PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, 2013, VOL 4 | 2014年
关键词
Medical Devices; Regulations; Design for FDA; Regression; DEVELOPMENT CYCLE TIME; PRODUCT DEVELOPMENT; COMPLEXITY; ENSEMBLES; PROJECT; MARKET;
D O I
暂无
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
The concept of Design for FDA (DfFDA) has a strong basis on the Food and Drug Administration's (FDA) regulation for medical devices in the Unites States. In fact; an analysis of the factors that impact the time it takes the FDA's to provide market approval for medical devices, the product design process model, and Design for X (DfX) methods with overlapping FDA objectives lead to the development of DfFDA as a means to increase awareness about regulatory compliance and promote designers to consider the regulations throughout the development process of medical devices. For doing so, the main objective of DfFDA is to provide regulation-focused guidelines to producers of medical devices. An important part of these guidelines and this paper's major contribution is the development of a prediction model for the FDA's decision time. Overall, we want this model to become a tool that allows medical device companies to come up with an accurate estimate of a product's time-to-market after accounting for the FDA's decision time. In this work, we provide a comparison and discussion on the adequacy of linear regression models and other non-linear models such as parallel and serial tree-based ensembles for prediction the FDA's decision time.
引用
收藏
页数:9
相关论文
共 35 条
  • [21] The power of public-private partnership in medical technology innovation: Lessons from the development of FDA-cleared medical devices for assessment of concussion
    Singer, Michael E.
    Hack, Dallas C.
    Hanley, Daniel F., Jr.
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 6 (01)
  • [22] Just-In-Time Education of FDA Regulation and Protection of Intellectual Property for Medical Products: A Course Review After Our First 10 Years
    Joan E. Adamo
    Erin L. Keegan
    John W. Boger
    Amy L. Lerner
    Biomedical Engineering Education, 2024, 4 (2): : 225 - 234
  • [23] Assessment of CFD Performance in Simulations of an Idealized Medical Device: Results of FDA's First Computational Interlaboratory Study
    Stewart S.F.C.
    Paterson E.G.
    Burgreen G.W.
    Hariharan P.
    Giarra M.
    Reddy V.
    Day S.W.
    Manning K.B.
    Deutsch S.
    Berman M.R.
    Myers M.R.
    Malinauskas R.A.
    Cardiovascular Engineering and Technology, 2012, 3 (02) : 139 - 160
  • [24] Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis
    Moon, John T.
    Konstantinidis, Menelaos
    Song, Nevon
    Nezami, Nariman
    Majdalany, Bill S.
    Herr, Allen
    Siskin, Gary
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
  • [25] Why did the number of US FDA medical device guidelines begin to rise in the mid-2010s? A perspective
    Daizadeh, Iraj
    EXPERT REVIEW OF MEDICAL DEVICES, 2022, 19 (12) : 921 - 939
  • [26] Singular secular Kuznets-like period realized amid industrial transformation in US FDA medical devices: a perspective on growth from 1976 to 2020
    Daizadeh, Iraj
    EXPERT REVIEW OF MEDICAL DEVICES, 2022, 19 (10) : 745 - 756
  • [27] Providing Software as a Service: a design decision(s) model
    Dutt, Abhijit
    Jain, Hemant
    Kumar, Sanjeev
    INFORMATION SYSTEMS AND E-BUSINESS MANAGEMENT, 2018, 16 (02) : 327 - 356
  • [28] The FDA's standard-making process for medical digital health technologies: co-producing technological and organizational innovation
    Lievevrouw, Elisa
    Marelli, Luca
    Van Hoyweghen, Ine
    BIOSOCIETIES, 2022, 17 (03) : 549 - 576
  • [29] RETRACTED ARTICLE: Seasonal and Secular Periodicities Identified in the Dynamics of US FDA Medical Devices (1976–2020): Portends Intrinsic Industrial Transformation and Independence of Certain Crises
    Iraj Daizadeh
    Therapeutic Innovation & Regulatory Science, 2022, 56 : 104 - 116
  • [30] Qualification of a non-animal vaginal irritation method admitted as nonclinical assessment model (NAM) in the Incubator Phase of the United States Food and Drug Administration (US FDA) Medical Devices Development Tool (MDDT)
    Costin, G-E.
    Hill, E.
    Brown, J.
    Clippinger, A. J.
    TOXICOLOGY IN VITRO, 2020, 62